Trial reportBMC musculoskeletal disorders2025
The effects of TECAR therapy on pain, range of motion, strength and subscale of HAGOS questionnaire in athletes with chronic adductor related groin pain: a randomized controlled trial.
Trial report in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Non-Invasive Radiofrequency Therapy for Musculoskeletal, Neurological, and Vascular Conditions of the Lower Limb: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Short-Term Effects of Capacitive and Resistive Electric Transfer Therapy and Static Splinting in the Management of Trigger Finger: A Non-Randomized Clinical Study.Life (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGroin pain is a common issue among athletes. Adductor-related pain is known as the most common cause of groin pain. Although, non-operative treatments have limited efficacy, Capacitive and Resistive Energy Transfer (TECAR), can be used in the treatment of musculoskeletal conditions. The objective of the present study is to explore the effect of TECAR therapy on pain, range of motion (ROM), strength, and subscales of the "Copenhagen Thigh and Groin Assessment Scale"(HAGOS) questionnaire in athletes suffering from adductor-related groin pain (ARGP).
methodsThis study was a two arm parallel groups randomized sham-controlled superiority trial. A total of 22 male professional athletes (mean age 21.36 years) were randomly assigned to either the real TECAR therapy (n = 11) or sham TECAR therapy (n = 11) group, using block-balanced randomization. Both groups received stretching exercises. Intervention group received 10 sessions of TECAR therapy while, the control group received sham TECAR therapy. Primary outcome was pain that was measured by Visual Analogue Scale (VAS). Secondary outcomes included ROM, strength, and HAGOS questionnaire subscales. All outcomes were assessed at baseline, after 5 sessions, after 10 sessions, and one month after treatment. Analysis of Variance (ANOVA) and Analysis of Covariance were used to compare between-group mean differences. P-value was set at 0.05. Effect size Cohen's d was also reported. This study took place from September 2022 to August 2023 at the Rehabilitation Clinic at Iran University of Medical Sciences.
resultsA total of 22 male athletes were included (11 in each group), with a mean age of 21.09 years in the TECAR group and 21.63 years in the sham group. TECAR therapy was associated with significant reductions in pain intensity across all evaluation sessions. Specifically, after 5 sessions, there was a large effect size for pain reduction (p = 0.01, Cohen's d = -1.09 [95% CI: -0.195 to -1.987]); after 10 sessions, the effect was even larger (p = 0.001, Cohen's d = -2.153 [95% CI: -1.103 to -3.203]); and at the 1-month follow-up, the pain reduction persisted (p = 0.001, Cohen's d = -1.96 [95% CI: -0.944 to -2.978]). In terms of secondary outcomes, there was a significant improvement in hip adduction ROM at the 1-month follow-up (p = 0.03, Cohen's d = 0.908 [95% CI: 0.03 to 1.78]). However, no statistically significant differences were found for other secondary outcomes, with effect sizes ranging from no effect to intermediate.
conclusionThe results of this study suggest that TECAR therapy may reduce pain and improve hip adduction range of motion in athletes with adductor-related groin pain.
trial registrationThis trial was registered at the ( https://www.irct.ir ), (IRCT20220622055250N1) on 18/09/2022.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.